NSE: MANKIND | BSE: 543904

Expensive Performer

Download real time

2384.70 97.70 (4.27%)

High volume today

NSE 02 Jul, 2025 3:31 PM (IST)

98,423.4

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Mankind Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for MANKIND, BSE:543904 Mankind Pharma Ltd.

Mankind Pharma Ltd.

24 Apr 2023

2384.70

4.27%

IPO Note

IPO Subscribe: Mankind Pharma Ltd.

Canara Bank Securities

Mankind Pharma Ltd. (“Mankind”) is India’s 4th largest pharmaceutical company in terms of Domestic sales and 3 rd largest in terms of sales volume for MAT (Moving An nual Total) December 2022 engaged in diverse range of pharmaceutical formulation across acute and chronic therapeutic areas.

Mankind Pharma Ltd.'s price crossed above 30Day SMA today

Mankind Pharma Ltd.

24 Apr 2023

2384.70

4.27%

Mankind Pharma Limited

IPO Subscribe: Mankind Pharma Ltd.

Asit C Mehta Investment Interrmediates

Mankind benefits from the industry experience and business acumen of their individual Promoters and is driven by the 3 core values of quality, affordability and accessibility. Their professional and experienced management team has been critical in building their brands, growing their operations, and maintaining capital efficiency despite their emphasis on affordable product offerings.

Number of FII/FPI investors increased from 624 to 640 in Mar 2025 qtr.

Mankind Pharma Ltd.

24 Apr 2023

2384.70

4.27%

Strong domestic market position through a diversified product portfolio

IPO Subscribe: Mankind Pharma Ltd.

Aditya Birla Money Limited

MPL focuses primarily on the domestic market (98% of sales) with market share increasing from 4.1% to 4.3% over FY20 - MAT Dec’22 with sales growing at 12% CAGR v/s IPM (Indian Pharmaceutical Market) growth of around 10% for the same period.

Mankind Pharma Ltd. has an average target of 2784.33 from 3 brokers.

Mankind Pharma Ltd.

24 Apr 2023

2384.70

4.27%

Mankind Pharma Ltd. IPO Note

IPO Note: Mankind Pharma Ltd.

Ashika Research

Mankind Pharma Ltd. is trading below its 50 day SMA of 2424.6

Mankind Pharma Ltd.

24 Apr 2023

2384.70

4.27%

Mankind Pharma Ltd: IPO

IPO Subscribe: Mankind Pharma Ltd.

ICICI Direct

Mankind Pharma Ltd.'s price crossed above 30Day SMA today

Mankind Pharma Ltd.

21 Apr 2023

2384.70

4.27%

Leading domestic pharma player with diverse product portfolio

IPO Subscribe: Mankind Pharma Ltd.

Geojit BNP Paribas

Mankind Pharma Ltd (MPL) is the fourth largest pharmaceutical company in India by domestic sales and third largest by sales volume. With 97% of its revenue from India, MPL sells pharmaceutical formulations and consumer healthcare goods, and operates 25 manufacturing sites and a specialised R&D centre with four divisions.

Mankind Pharma Ltd.'s price crossed above 30Day SMA today

Mankind Pharma Ltd.

20 Apr 2023

2384.70

4.27%

IPO Note - Mankind Pharma Limited 20042023

IPO Note: Mankind Pharma Ltd.

HDFC Securities

Issue Snapshot: Issue Open: Apr 25 Apr 27, 2023 Price Band: Rs. 1026 1080 *Issue Size: 4326.36 cr (Entirely Offer for Sale of 40,058,844 eq sh) Reservation for: QIB upto 50% eq sh Non-Institutional atleast 15% eq sh ((including 1/3rd for applications between Rs.2 lakhs to Rs.10 lakhs)) Retail atleast 35% eq sh Face Value: Rs 1 Book value: Rs 178.38 (December 31, 2022) Bid size: - 13 equity shares and in multiples thereof 100% Book built Issue IPO Note - Mankind Pharma Limited

Mankind Pharma Ltd. is trading above its 30 day SMA of 2370.6

Mankind Pharma Ltd.

20 Apr 2023

2384.70

4.27%

Domestic leader gears up for listing

IPO Subscribe: Mankind Pharma Ltd.

Centrum Broking

Mankind is a well?known player in the domestic pharma market (with 97.6% of sales), and is 4th largest in terms of sales and 3rd largest in terms of sales volume as on Dec’22 MAT. About 36 brands in the Pharma business, which has sales over Rs500mn, with strong brand positioning. In the consumer segment, it has leading brands i.e Manforce, Prega News, Unwanted?72, which are having significant market share in their
respective categories.